GT
GT Biopharma, Inc.
GTBP · NASDAQ
$7.49 -1.38% (-$0.10)
1M +8.93%
Market Cap $9.45M
P/E Ratio -
Div. Yield -
ROE 443.08%
Bulios Fair Price
$5.11
31.8% downside
Current Price
$7.49
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GTBP is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
73 /100
Cheap P/B 2.65x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 20.99%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 457.75%
Asset turnover 0.00x
ROE 443.08%
Debt
69 /100
Low Debt/Equity 0.00x
Int. coverage -160.04x
Current ratio 2.61x
Stability
36 /100
Moderate Beta 0.91x
Profitable years 0
EPS volatility 432.17%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GTBP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Martin Breen
Employees
1
Headquarters
San Francisco
Upcoming events
13 NOV
Earnings
Upcoming earnings report